1
Ten patients were assigned to receive hydrocortisone treatment and the other 10 to receive placebo.
2
Patients who were not initially randomized to receive placebo continued to receive their target apremilast dose.
3
Results: Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine.
4
A total of 1705 patients were assigned to receive antibiotics and 1707 to receive placebo.
5
Ten subjects were enrolled at each dose level (eight randomized to receive PMPA and two randomized to receive placebo).
6
One-half of the subjects were randomly allocated to receive vaccine and the other one-half to receive placebo, in double blind fashion.
7
Results: Among the 163 patients, 77 were randomized to receive bosentan, and 86 were randomized to receive placebo.
8
Results: Of the 391 patients who underwent randomization, 260 were assigned to receive olaparib and 131 to receive placebo.
9
We enrolled 332 patients: 111 were assigned to receive placebo, 110 to 5 mg CCX140-B, and 111 to 10 mg CCX140-B.
10
Findings: Between April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and 320 to receive placebo.
11
They recruited 163 adults diagnosed with opioid dependence and randomly assigned 108 to get the implants and 55 to receive placebo implants.
12
We randomly assigned 762 patients to receive dofetilide, a novel class III antiarrhythmic agent, and 756 to receive placebo in a double-blind study.
13
Methods: Before sitaxsentan withdrawal, this 18-week double-blind, placebo-controlled study randomized patients with PAH to receive placebo or sitaxsentan 50 or 100 mg once daily.
14
Results: Of 166 patients enrolled, 83 were allocated to receive G-CSF (81 included in analysis) and 83 were allocated to receive placebo.
15
Findings: Between May 23, and July 1, 2013, 1761 children were randomly assigned, 1174 to receive live attenuated influenza vaccine and 587 to receive placebo.
16
None of the 116 patients receiving placebo had a sustained virologic response.
